Members |
acceptabilityId |
% chlorure de sodium |
Preferred (foundation metadata concept) |
'bubble' gastrique |
Acceptable (foundation metadata concept) |
'shaving' |
Preferred (foundation metadata concept) |
'shaving' de la patella |
Preferred (foundation metadata concept) |
'shaving' endoscopique d'un cartilage articulaire |
Preferred (foundation metadata concept) |
'strapping' d'un pied bot |
Preferred (foundation metadata concept) |
'strapping' patellaire |
Preferred (foundation metadata concept) |
'stress test' articulaire négatif |
Preferred (foundation metadata concept) |
'stress test' articulaire positif |
Preferred (foundation metadata concept) |
'stress test' cervical négatif |
Preferred (foundation metadata concept) |
'stress test' cervical positif |
Preferred (foundation metadata concept) |
'stripping' |
Preferred (foundation metadata concept) |
'stripping' d'un os |
Preferred (foundation metadata concept) |
'stripping' d'une veine saphène variqueuse |
Preferred (foundation metadata concept) |
'stripping' de l'enthèse calcanéenne d'un muscle intrinsèque du pied |
Preferred (foundation metadata concept) |
'stripping' de la grande veine saphène |
Preferred (foundation metadata concept) |
'stripping' de la petite veine saphène |
Preferred (foundation metadata concept) |
'stripping' et ligature de la grande veine saphène |
Preferred (foundation metadata concept) |
'stripping' et ligature veineuse de la jambe |
Preferred (foundation metadata concept) |
'stripping' et ligature veineuse du membre inférieur |
Preferred (foundation metadata concept) |
'stripping' veineux |
Preferred (foundation metadata concept) |
'stroke test' du genou |
Preferred (foundation metadata concept) |
(s)- tricyclamol |
Preferred (foundation metadata concept) |
0,5 |
Preferred (foundation metadata concept) |
0,5 mL de poudre en flacon du vaccin vivant contre la rubéole |
Preferred (foundation metadata concept) |
0215 x 028 |
Preferred (foundation metadata concept) |
1,1,1,2-tétrachloro 2,2-difluoroéthane |
Preferred (foundation metadata concept) |
1,1,1-trichloroéthane |
Preferred (foundation metadata concept) |
1,1,2,2-tétrachloro 1,2-difluoroéthane |
Preferred (foundation metadata concept) |
1,1-dichlorobutane |
Preferred (foundation metadata concept) |
1,2-dichloroéthylène |
Preferred (foundation metadata concept) |
1,25-dihydroxy-vitamine D |
Acceptable (foundation metadata concept) |
1,3-dichloro-2-propanol |
Preferred (foundation metadata concept) |
1,3-dichloro-2-propanol (substance) |
Preferred (foundation metadata concept) |
1-1-bis-(p-chlorophényl)-2-nitrobutane |
Preferred (foundation metadata concept) |
1-1-bis-(p-chlorophényl)-2-nitropropane |
Preferred (foundation metadata concept) |
1-1-dichloro-1-nitroéthane |
Preferred (foundation metadata concept) |
1-chloro-1-nitropropane |
Preferred (foundation metadata concept) |
1-chloro-1-nitropropane (substance) |
Preferred (foundation metadata concept) |
1-chloro-1-nitroéthane |
Preferred (foundation metadata concept) |
1/2 mouvement |
Preferred (foundation metadata concept) |
1/4 de mouvement |
Preferred (foundation metadata concept) |
10 microgrammes de polysaccharides contre l'Haemophilus influenzae et 24 microgrammes d'anatoxine tétanique |
Preferred (foundation metadata concept) |
10 µg/0,5 ml du vaccin contre l'hépatite B recombinant |
Preferred (foundation metadata concept) |
10^2 |
Preferred (foundation metadata concept) |
10^3 |
Preferred (foundation metadata concept) |
10^4 |
Preferred (foundation metadata concept) |
10^5 |
Preferred (foundation metadata concept) |
10^6 |
Preferred (foundation metadata concept) |
10^7 |
Preferred (foundation metadata concept) |
10^e^ au 25^e^ centile |
Preferred (foundation metadata concept) |
10e étage |
Acceptable (foundation metadata concept) |
11-désoxycorticostérone |
Acceptable (foundation metadata concept) |
11e étage et étages supérieurs |
Acceptable (foundation metadata concept) |
12 heures |
Preferred (foundation metadata concept) |
123i-iode |
Preferred (foundation metadata concept) |
123i-iode iobenguane |
Preferred (foundation metadata concept) |
153sm-samarium lexidronam |
Acceptable (foundation metadata concept) |
16 x 16 |
Preferred (foundation metadata concept) |
16 x 22 |
Preferred (foundation metadata concept) |
17 x 22 |
Preferred (foundation metadata concept) |
17 x 25 |
Preferred (foundation metadata concept) |
18 x 22 |
Preferred (foundation metadata concept) |
18 x 25 |
Preferred (foundation metadata concept) |
18f-florbétabène |
Preferred (foundation metadata concept) |
18f-fluorodopa |
Preferred (foundation metadata concept) |
1:03 |
Preferred (foundation metadata concept) |
1:06 |
Preferred (foundation metadata concept) |
1:1,5 |
Preferred (foundation metadata concept) |
1:9 |
Preferred (foundation metadata concept) |
1er étage |
Acceptable (foundation metadata concept) |
2 heures |
Preferred (foundation metadata concept) |
2,3-époxy-1-propanol |
Preferred (foundation metadata concept) |
2,4-diisocyanate de toluène |
Preferred (foundation metadata concept) |
2,4-toluènediamine |
Preferred (foundation metadata concept) |
2,6-toluènediamine |
Preferred (foundation metadata concept) |
2-acétylaminofluorine |
Preferred (foundation metadata concept) |
2-amino-5-nitrothiazole |
Preferred (foundation metadata concept) |
2-amino-5-nitrothiazole (substance) |
Preferred (foundation metadata concept) |
2-bromo-4-phénylphénol |
Preferred (foundation metadata concept) |
2-chloro-4-nitrobenzamide |
Preferred (foundation metadata concept) |
2-chloroéthanol |
Preferred (foundation metadata concept) |
2-hydroxy-2,2-bis-(4-chlorophényl)éthyl acétate |
Preferred (foundation metadata concept) |
2-méthoxy-p-crésol |
Preferred (foundation metadata concept) |
2-méthylbutyrylglycinurie |
Preferred (foundation metadata concept) |
2-éthylhexyl-2-cyano-3,3-diphénylacrylate |
Preferred (foundation metadata concept) |
21 x 25 |
Preferred (foundation metadata concept) |
21-hydroxyprogestérone |
Acceptable (foundation metadata concept) |
24 heures |
Preferred (foundation metadata concept) |
25^e^ au 50^e^ centile |
Preferred (foundation metadata concept) |
2e étage |
Acceptable (foundation metadata concept) |
3,4-diaminopyridine |
Preferred (foundation metadata concept) |
3-3,dichlorobenzidine |
Preferred (foundation metadata concept) |
3-alpha-allo-tétrahydrocortisol |
Preferred (foundation metadata concept) |
3-méthoxyaniline |
Preferred (foundation metadata concept) |
3-phényl-salicylate de cuivre |
Preferred (foundation metadata concept) |
3/4 de mouvement |
Preferred (foundation metadata concept) |
30 mm |
Preferred (foundation metadata concept) |
3^e^ au 10^e^ centile |
Preferred (foundation metadata concept) |
3e étage |
Acceptable (foundation metadata concept) |
4 heures |
Preferred (foundation metadata concept) |